Partnering Webinars

1. Best Practices For Operationalizing Global, Early-Phase Oncology Trials 9/10/2025

   In this presentation, industry experts will share real-world lessons learned from managing global early-phase oncology trials.

2. Clinical Leader Smart Sourcing Solutions Expo: Retention By Design 9/9/2025

   Enhance participant retention through intuitive UX and real-time site support tools, while seamlessly integrating with IRT, EDC, and third-party platforms.

3. Australia's R&D Incentive: Not A Gift, But A Tax Strategy 9/4/2025

   Mike Burfield explains that the 43.5% R&D incentive is often misunderstood as free money. In reality, it’s a tax program requiring eligible entities, deductible R&D spend, and clear paths to revenue. Foreign sponsors must align tax, corporate, and transfer-pricing rules to benefit.

4. Why Australia's Clinicians Make Site Selection Easier 9/4/2025

   In this short clip, Megan Robertson outlines how sponsors should approach site selection in Australia. She emphasizes the strength of clinician networks and collaborative trial groups, noting that key opinion leaders can connect sponsors to top sites. She also stresses that sites only take on studies they can realistically recruit for, which improves trial efficiency.

5. The Power of Clinical Trial Networks in Australia 9/4/2025

   This clips shows how Australia’s 80+ clinical trial networks, advocacy groups, and telehealth capabilities help sponsors find and recruit patients more effectively. Tina Soulis contrasts this with the US, where sponsors often need far more sites to hit enrollment targets, noting Australia’s smaller but highly concentrated patient populations.

6. Why Biotechs Choose Australia for First-in-Human Trials 9/4/2025

   Tina Soulis details Australia’s advantages for early-stage trials, including tax incentives, no IND requirement, and flexibility in trial design. She describes the typical biotech client profile and explains how adaptive trials are increasingly common. Tina also highlights that Australian-generated data is accepted by global regulators, strengthening biotech strategies.

7. How Clinical Trials Are Approved in Australia 9/3/2025

   Megan Robertson explains the Australian process for authorizing trials. Unlike the US, where the FDA approves first, Australia delegates reviews to Human Research Ethics Committees (HRECs). Once approved, sponsors notify the Therapeutic Goods Administration (TGA), which acknowledges within two weeks. She highlights how nearly all studies use this streamlined Clinical Trial Notification (CTN) pathway.

8. Rethinking CRO Deposits: Russell's Alternative To Frozen Capital 9/3/2025

   Instead of handing CROs a hefty security deposit — often $500K to $1M locked away for years — Russell Hayward negotiated milestone-based payments. He warns that traditional deposits tie up capital, can’t be expensed, and deliver no return, making them a major risk for small biotechs.

9. Partnering With Functional Service Providers 8/27/2025

   In this presentation, we gain insights into how a culture-forward FSP framework enhances operational efficiency, strengthens partnerships, and helps organizations adapt to growingly complex research.

10. An Innovative Approach To Functional Outsourcing 8/27/2025

    The shifting dynamics of clinical research from the current funding dynamic to the increased complexity of drug development, requires a different approach to functional outsourcing to be successful.